geron corporation biotechnology company located foster city california specializes developing commercializing therapeutic products cancer inhibit telomerase geron based foster city california founded gerontologist mary c west michael west ceo agex secured initial venture capital investments company kleiner perkins caufield byers company incorporated began business john scarlett appointed ceo companys scientific clinical advisory board included nobel laureates james watson gunter blobel carol greider leonard hayflick known discovering human cells divide limited number times called hayflick geron staff received highest median pay california geron corporation sponsored human clinical trials several potential anticancer products addition testing drug candidates exploit cancer cells dependence telomerase geron researching possible applications activating enzyme normal cells delay cellular senescence company early stages developing telomerase based treatment hiv called saponin cycloastragenol chinese herb astragalus geron granted license telomerase activation sciences sell telomerase activator agent also derived october intertekaac labs iso internationally recognized lab found largest component geron originally investigated telomerase means understanding modifying human aging however geron ceased aging research january geron received fda approval begin phase testing embryonic stem cell based drug designed treat specific forms spinal cord injury remyelination damaged axons trial involve direct use stem cells however composed oligodendrocyte progenitor cells derived embryonic stem cell lines studies shown significant restoration mobility animals spinal injuries received geron also several embryonic stem cell treatments still preclinical phase including treatment heart disease treatment diabetes tests diabetic mice mice given still alive days entire control group given treatment geron sold human stem cell research assets asterias october november one gerons highly publicized trial therapy products stem cell therapy designed heal severe spinal cord injuries cells therapy coaxed becoming early myelinated glial cells type cell insulates nerve cells every cell injected patient become six ten cells october updated results four patients trial discontinued nov early biotime whose ceo time geron founder michael west acquired patents intellectual property related embryonic stem cells later went restart geron corporation initially held exclusive rights three cell types derived embryonic stem cells result paying research originally conducted dr james thomson university patents three cell types owned wisconsin alumni research foundation warf warf geron charge academics study human stem cells charge commercial users warf came public pressure widen access human stemcell technology launched legal action geron corporation recover previously sold rights two sides agreed geron would keep rights three cell october legal challenge mounted overturn patents foundation taxpayer consumer rights nonprofit patentwatchdog public patent contended two patents granted warf invalid cover technique published patent already granted australian researcher another part challenge came molecular biologist jeanne loring stated university stem cell pioneer james thomsons techniques currently patents held warf rendered obvious paper two outcome legal challenge particularly relevant geron corporation license patents patents ultimately upheld reexamination concluded interim measure january warf relaxed stem cell patents allowing industrysponsored research academic nonprofit institutions without warf allow easier simpler cost free cell transfers among researchers would require license agreement californias taxpayerfunded stem cell research participant thencontroversial stem cell cloning area geron corporation asked testify technology us congress congress attempting ban forms cloning geron ceo thomas okarma spoke congress preserve cloning therapeutic httpsenwikipediaorgwikigeroncorporation